FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial

Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer

(2020) Jane E. Rogers et al.   ONCOLOGY

Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study

(2020) Akihito Kawazoe et al.   EUROPEAN JOURNAL OF CANCER

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer

(2020) Carlotta Antoniotti et al.   BMC CANCER

Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real‐life data

(2020) Patricia A. H. Hamers et al.   INTERNATIONAL JOURNAL OF CANCER

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

(2020) Thierry André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

(2019) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunotherapy in colorectal cancer: rationale, challenges and potential

(2019) Karuna Ganesh et al.   Nature Reviews Gastroenterology & Hepatology

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study

(2019) Yung-Jue Bang et al.   Gastric Cancer

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

(2019) Scott Kopetz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

(2019) Dung T. Le et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

(2019) Robert J Motzer et al.   LANCET ONCOLOGY

Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer

(2018) Rona Yaeger et al.   CANCER CELL

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)

(2018) N Boku et al.   ANNALS OF ONCOLOGY

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

(2018) Frank Stephen Hodi et al.   LANCET ONCOLOGY

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

P-278Phase Ib/II study of nivolumab plus CAPIRI: Initial results of metastatic colon cancer and pancreatic adenocarcinoma patients

(2016) V. Khemka et al.   ANNALS OF ONCOLOGY

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

(2016) E. Van Cutsem et al.   ANNALS OF ONCOLOGY

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

(2015) Chiara Cremolini et al.   LANCET ONCOLOGY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort

(2015) Halfdan Sorbye et al.   PLoS One

Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

(2014) Fotios Loupakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Smaller sample sizes for phase II trials based on exact tests with actual error rates by trading-off their nominal levels of significance and power

(2012) I Khan et al.   BRITISH JOURNAL OF CANCER

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

(2009) F Loupakis et al.   BRITISH JOURNAL OF CANCER